ABSTRACT
The use of supramolecular synthons as a strategy to control crystalline structure is a crucial factor in developing new solid forms with physicochemical properties optimized by design. However, to achieve this objective, it is necessary to understand the intermolecular interactions in the context of crystal packing. The feasibility of a given synthon depends on its flexibility to combine the drug with a variety of coformers. In the present work, the imidazole-hydroxy synthon is investigated using as the target molecule benzoylmetronidazole [BZMD; systematic name 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl benzoate], whose imidazole group seems to be a suitable acceptor for hydrogen bonds. Thus, coformers with carboxylic acid and phenol groups were chosen. According to the availability of binding sites presented in the coformer, and considering the proposed synthon and hydrogen-bond complementarity as major factors, different drug-coformer stoichiometric ratios were explored (1:1, 2:1 and 3:1). Thirteen new solid forms (two salts and eleven cocrystals) were produced, namely BZMD-benzoic acid (1/1), C13H13N3O4·C7H6O2, BZMD-ß-naphthol (1/1), C13H13N3O4·C10H8O, BZMD-4-methoxybenzoic acid (1/1), C13H13N3O4·C8H8O3, BZMD-3,5-dinitrobenzoic acid (1/1), C13H13N3O4·C7H4N2O6, BZMD-3-aminobenzoic acid (1/1), C13H13N3O4·C7H7NO2, BZMD-salicylic acid (1/1), C13H13N3O4·C7H6O3, BZMD-maleic acid (1/1) {as the salt 1-[2-(benzoyloxy)ethyl]-2-methyl-5-nitro-1H-imidazol-3-ium 3-carboxyprop-2-enoate}, C13H14N3O4+·C4H3O4-, BZMD-isophthalic acid (1/1), C13H13N3O4·C8H6O4, BZMD-resorcinol (2/1), 2C13H13N3O4·C6H6O2, BZMD-fumaric acid (2/1), C13H13N3O4·0.5C4H4O4, BZMD-malonic acid (2/1), 2C13H13N3O4·C3H2O4, BZMD-2,6-dihydroxybenzoic acid (1/1) {as the salt 1-[2-(benzoyloxy)ethyl]-2-methyl-5-nitro-1H-imidazol-3-ium 2,6-dihydroxybenzoate}, C13H14N3O4+·C7H5O4-, and BZMD-3,5-dihydroxybenzoic acid (3/1), 3C13H13N3O4·C7H6O4, and their crystalline structures elucidated, confirming the robustness of the selected synthon.
